Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Global Dominance in AI? China’s Got a Plan For That
Posted on July 9th, 2019 by Xuanyan Xu in Pharma R&D
Artificial intelligence is more than just a ‘hot topic’ in the pharmaceutical industry—it is actually influencing the way that major industry players and even entire nations are thinking about the future. As more AI-focused companies are launching, and as investment in AI technology is increasing in the US and EU, China is speeding up its efforts to ensure that it can be competitive in this burgeoning area.
(more…)Healthcare Organizations, Including Major Pharmas, Band Together to Form AI-focused Group
Posted on June 26th, 2019 by Jabe Wilson in Pharma R&D
Artificial intelligence continues to gain momentum across industries as people start to better realize its potential benefits. Healthcare is no exception, as industry players understand that AI and machine learning can do much to improve patient treatment and care. Now, some in this sector want to do more to address the burgeoning challenges of AI head-on.
(more…)AI in Drug Discovery Has Great Potential – But Also Significant Barriers
Posted on May 1st, 2019 by Nicki Catchpole in Pharma R&D
Elsevier’s Tim Miller’s article in World Pharma Today provides a insightful lens into the reality behind the complexities of implementing artificial intelligence into the R&D cycle. While great strides have been made, the runway to realize the potential is a long one and there are many exciting discoveries left to be made and obstacles to overcome.
(more…)Three factors to unlock the value of AI for life sciences
Posted on May 1st, 2019 by Christy J. Wilson in Pharma R&D
Artificial Intelligence (AI) has been at the top of many boardroom agendas for the last several years, as execs try to integrate the technology. Recent RELX research found that, across all industries, 88 percent of senior executives believe AI will help their businesses be more competitive. In the life sciences, AI has the potential to scale the benefits of precision medicine or automated disease prediction to more patients across the world, and could generate more than $150 billion in savings for the healthcare industry by 2025.
